Three patients (two with H-CCK and one with HCC) having alterations in CDK4, HER2, and TSC2 achieved disease control with palbociclib, trastuzumab/olaparib, and everolimus, respectively. This evidence concerns the gene TSC2 and hepatocellular carcinoma.